Last updated 2026-09-06
- Raised $5M Undisclosed Round led by Ron Pfeifer, Aug 2018
Total raised
$5.0M
Stage
Pre-Funding
Founded
2007
Headcount
2
HQ
Mevaseret Zion, Israel
Sector
Drug Discovery
Website ↗Registrar ID: 513954016 (Immunity Pharma Ltd.)
About
Immunity Pharma is a drug development company focused on developing therapies for neurodegenerative diseases, particularly Amyotrophic Lateral Sclerosis (ALS). The company's approach, licensed from the Weizmann Institute of Science, involves using switch-peptides with biologic activity that enhances natural self-repair processes of the immune system. Their lead candidate, IPL344, is a peptide-based anti-apoptotic drug that aims to activate the Akt pathway to slow or halt ALS progression. IPL344 has completed preclinical trials and has shown positive results in Phase 2a studies for ALS patients.
Funding history · 1 round · $5.0M total
1 event/round · $5.0M Total Funding: $5.0M in Private Equity
Aug 2018
★ Ron Pfeiferfund managers
Headcount over time
2 employees (2026-09) · 1 point
Offices
Mevaseret Zion, Israel · HQ / main office
Q&A
- What is Immunity Pharma's primary focus in drug development?
- Immunity Pharma primarily focuses on developing therapies for neurodegenerative diseases, with an initial emphasis on amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease.
- What type of drugs does Immunity Pharma develop?
- Immunity Pharma develops peptide-based drugs with biologic activity that stimulate therapeutic cell-signaling processes.
- What is the current clinical trial status of Immunity Pharma's lead drug, IPL344?
- Immunity Pharma's lead drug, IPL344, is currently entering an open-label, phase-1/2a clinical trial with ALS patients.
- Where did the research for IPL344 originate?
- IPL344 originated from the research laboratory of Professor Irun Cohen at the Weizmann Institute of Science in Israel.
- How many employees does Immunity Pharma have?
- Immunity Pharma has 1-10 employees.
- When was Immunity Pharma founded?
- Immunity Pharma was founded in March 2007.
- What is Immunity Pharma's current funding stage?
- Immunity Pharma is currently in the Pre-Funding stage.
- Who is the CEO of Immunity Pharma?
- Eran Ovadia is the CEO of Immunity Pharma.
Team · 7
Eran Ovadia
Founder · CEO
Ilana Cohen
Founder · VP R&D
Oren M. Becker, Ph.D.
Founder · Board Member
Tamar Oved, PhD
QA and CMC Director
Lital Israeli-Yagev
Regulatory Affairs Director
Ron Pfeifer
Chairperson of the Board
Gideon Stein, Ph.D.
Board Member
Tags
treatmentsdegenerative-diseasespharmaceuticalsamyotrophic-lateral-sclerosis-alsinflammatory-diseases
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | immunitypharma.com |
|---|
Identifiers & details
| Legal name | Immunity Pharma Ltd. |
|---|---|
| Founded | 2007-3 |
| Employees (exact) | 2 |
Radar intelligence
Patents
| EPO | 4 |
|---|
Web history (Wayback)
| Domain | immunitypharma.com |
|---|
Certificate / subdomain footprint
| Subdomains | 3 |
|---|
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 513954016 |
|---|---|
| Status | פעילה |
| Corp type | ישראלית חברה פרטית |
| Incorporated | 2007-03-14 |
| Purpose | לעסוק בכל עיסוק חוקי |
| Liability | מוגבלת |
| In violation (unfiled) | no |
| Last annual report | 2026 |
| Active charges / liens | 0 |
| Registry events | 3 — shares_capital (1), annual_report (1), violation (1) |
| Registered address | מירון 28 מבשרת ציון |
Recent registry events
| Date | Event |
|---|---|
| 2026-07-19 | הקצאת מניות |
| 2026-08-11 | דו~ח שנתי |
| 2026-06-01 | עדכון הפרה |